

# DORSET MEDICINES ADVISORY GROUP

## Recommendation Summary



**Dorset  
Clinical Commissioning Group**

**The Dorset Medicines Advisory Group (DMAG) includes representatives from the four provider Trusts, Public Health Dorset and GPs within the Clinical Commissioning Group (CCG). It advises the system on prescribing and commissioning of medicines in Dorset.**

Summary of recommendations made by the group 9<sup>th</sup> June 2020. Formulary entries and associated documents can be accessed at [www.dorsetformulary.nhs.uk](http://www.dorsetformulary.nhs.uk).

PRODUCT	DECISION		COMMENTS
<b>1. Products re-categorised</b>	<b>Previous position</b>	<b>Recommended position</b>	
Erythromycin	Amber	Green	In splenectomised patients to green from amber which brings it in line with the previous changes to the erythromycin status (DMAG January 2020).
Dermol 600	Green	Amber	In line with the bath/shower emollients already on the formulary.
<b>2. New requests</b>			
Humalog® 200 units/ml KwikPen.	Green		
Paravit-CF and DEKAs	Amber		Indicated for CF patients only. "Fat-soluble vitamin supplements for use when recommended by specialist in patients with cystic fibrosis. Specialists to ensure preferred formulation and dose is clearly communicated to primary care prescribers" as per UHS formulary. This will align the Dorset Formulary with Southampton Hospital where treatment is initiated.
Renapro Shot®	Amber		For the dietary management of dialysis patients with biochemically proven hypoproteinaemia on the recommendation of a specialist dietitian
Farco-Fill-IPC	non-formulary		Evidence is not strong enough to recommend use in Dorset

PRODUCT	DECISION	COMMENTS
AgaMatrix Ultra-Thin Lancets OneTouch Delica Plus Mylife lancets Glucosject Lancets PLUS GlucorX Lancets Accu-Chek FastClix GlucorX Safety Lancets Mylife Safety Lancets	Green	Supports primary care to make formulary choices, of lancets that fit the finger pricking devices, supplied with one or more of the blood glucose monitors currently on the formulary.
<b>3. Products considered by NICE</b>		
N/A		
<b>4. Miscellaneous recommendations by DMAG</b>		
Mefloquine and diving statement	Removal from the formulary	
<b>5. Further Assessment / Evidence Required</b>		
Lurasidone	non-formulary to red	The EMA studies and Lancet reviews of lurasidone that show it is less effective than others within its class and causes as much, if not more weight gain. The group therefore questioned the requirement to change formulary status. The group agreed that this recommendation should go back to the mental health working group for further discussion and evaluation by the experts. It was suggested the mental health working group look to support use only where a tertiary specialist centre has initiated treatment and recommends continuation.
<b>6. New documents approved</b>		

PRODUCT	DECISION	COMMENTS
N/A		
<b>7. Documents Reviewed</b>		
<ul style="list-style-type: none"> <li>• Shared Care Guideline for Attention deficit Hyperactivity disorder (ADHD) in adults aged over 17 years and in children and adolescents aged 6 to 17 years</li> <li>• Shared care guideline for prescribing Valproate in the treatment of Bipolar Disorder</li> <li>• Shared care guideline for Denosumab (Prolia®)</li> <li>• Pan Dorset guideline for the Management of Vitamin D Deficiency &amp; Insufficiency for adults</li> <li>• The prevention and management of glucocorticoid-induced osteoporosis</li> <li>• Dorset Algorithm for Osteoporosis Primary Prevention: Medical Management of Men &amp; Women who are (or are at risk of) Osteoporosis.</li> <li>• Shared care guideline for DMARDs in West Dorset</li> <li>• The updated preferred product list for urinary management</li> </ul>		

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset